

RECEIVED

AUG 17 2001

TECH CENTER 1600/2900

Sub Form PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
47508.700Application Number
09/708,786Applicant
AgrawalFiling Date
November 8, 2000Group Art Unit
1646

Sheet

1

OF

1

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/38964	Aug. 5, 1999	PCT				
	WO 96/17626	Jun. 13, 1996	PCT				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

A1	Potter, P.M., et al. "Isolation and Partial Characterization of a cDNA Encoding a Rabbit Liver Carboxylesterase That Activates the Prodrug Irinotecan (CPT-11)" <i>Cancer Research</i> , Vol. 58, (12), pp. 2646-2651 (1998)
A2	Kuhn, "Pharmacology on Irinotecan" <i>Oncology</i> , Supplemental No. 6, pp. 39-42 (1998)
A3	Cerosimo, "Irinotecan: A New Antineoplastic Agent for the Management of Colorectal Cancer" <i>The Annals of Pharmacotherapy</i> , No. 32, pp. 1324-1333 (1998)
A4	Singh, et al. "Prodrug Approach in New Drug Design and Development" <i>J. Sci. Ind. Res.</i> Vol. 55, pp. 497-510 (1996)
A5	Zon, "Oligonucleoside Phosphorothioates" <i>Methods in Molecular Biology</i> , Vol. 20, pp. 165-189 (1993)
A6	Zon, et al., "Phosphorothioate Oligonucleotides" <i>Oligonucleotides and Analogues: A Practical Approach</i> , pp. 87-108 (1991)
A7	Agrawal and Iyer, "Modified Oligonucleotides as Therapeutic and Diagnostic Agents" <i>Curr. Op. in Biotech.</i> , Vol. 6 (12) (1995)

EXAMINER

Lena C. Hill

DATE CONSIDERED

6/1/02

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON 1226216v1